Advanced Search

 

Study ID Status Title Patient Level Data
792014/001 Completed A phase II, open (partially double-blind), randomised, controlled, multicentre, primary vaccination study to evaluate the immunogenicity (including immune memory), reactogenicity and safety of three different formulations of the GSK Biologicals’ combined Haemophilus influenzae type b-meningococcal serogroups CY conjugate vaccine given concomitantly with Infanrix® penta and Prevenar®, versus ActHIB® and Meningitec® given concomitantly with Infanrix® penta and versus ActHIB® given concomitantly with Infanrix® penta and Prevenar® in infants according to a 2-4-6 month schedule. Study Listed on ClinicalStudyDataRequest.com
792014/002 Completed A phase II, open, randomized, controlled, multicentre, primary vaccination study to evaluate the immunogenicity, reactogenicity and safety of an investigational vaccination regimen versus ActHIB® and Menjugate® given concomitantly with Infanrix® penta and Prevenar® in infants Study Listed on ClinicalStudyDataRequest.com
792014/003 Completed A phase II, open (partially double-blind), randomised, controlled, multicentre, primary vaccination study to evaluate the immunogenicity, reactogenicity and safety of three different formulations of GSK Biologicals’ combined Haemophilus influenzae type b-meningococcal serogroups C and Y- conjugate vaccine and one formulation of GSK Biologicals’ Haemophilus influenzae type b-meningococcal serogroup C conjugate vaccine each given concomitantly with InfanrixTM penta, versus MeningitecTM, given concomitantly with InfanrixTM hexa in infants according to a 2-3-4 month schedule Study Listed on ClinicalStudyDataRequest.com
797620/001 Completed A dose proportionality study with a combination tablet formulation of rosiglitazone and glimepiride (4mg/1mg; or 4mg/2mg; or 4mg/4mg) in healthy subjects. Study Listed on ClinicalStudyDataRequest.com
797620/002 Completed A bioequivalence study with a combination tablet formulation of rosiglitazone and glimepiride (4mg/4mg) compared to concomitant dosing of rosiglitazone 4mg and glimepiride 4mg (4mg + 4mg) commercial tablets in healthy subjects Study Listed on ClinicalStudyDataRequest.com
797620/003 Completed A study to assess effect of food on pharmacokinetics of an investigational formulation, and to compare the pharmacokinetics of an investigational formulation to concomitant dosing of rosiglitazone 4mg and glimepiride 4mg commercial tablets in the fed state in healthy subjects Study Listed on ClinicalStudyDataRequest.com
797620/004 Completed A multi-center, randomized, double-blind, parallel group trial to compare the efficacy and safety of fixed-dose rosiglitazone/glimepiride combination therapy to glimepiride monotherapy and rosiglitazone monotherapy in drug naïve subjects with type 2 diabetes mellitus Study Listed on ClinicalStudyDataRequest.com
797629/003 Completed A study to assess the effect of food on pharmacokinetics of a rosiglitazone 4 mg and glimepiride 4 mg combination tablet formulation and to compare the pharmacokinetics of rosiglitazone 4 mg and glimepiride 4 mg combination tablet to concomitant dosing of rosiglitazone 4 mg and glimepiride 4 mg ...
811936/001 Completed Phase 2, open, randomized, controlled study to demonstrate the non-inferiority of the meningococcal serogroup C immune response and the superiority of the Hib immune response of GSK Biologicals’ Haemophilus influenzae type b-meningococcal C-TT conjugate vaccine administered with Infanrix™ penta versus Meningitec™ administered with Infanrix™ Study Listed on ClinicalStudyDataRequest.com
811936/003 Completed A phase 3, open, randomized, controlled, multicentre study to evaluate the safety and reactogenicity profile of GSK Biologicals' Haemophilus influenzae type b–meningococcal serogroup C conjugate candidate vaccine given concomitantly with GSK Biologicals' diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine and to compare it with MenC-CRM197 conjugate vaccine co-administered with GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine, when given as a 3-dose primary vaccination (at 2, 3, 4 months of age) to healthy infants. Study Listed on ClinicalStudyDataRequest.com
82 Completed The disposition of bupropion and its metabolites in healthy male volunteers after administration of single and multiple doses of bupropion.
83 Completed Treatment of Bulimia with Bupropion: A Multicenter Controlled Trial – Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citation below.
88 Completed Double-Blind Comparison of Bupropion and Fluoxetine in Depressed Outpatients – Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citation below.
89 Completed Six-week, parallel, double-blind, randomized comparison of bupropion and trazodone (150-400mg/day) in outpatients – Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citations below.
9 Completed Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients
90 Completed The Cardiovascular Effects of Bupropion and Nortriptyline in Depressed Outpatients – Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citation below.
95001 Completed A multicenter, concurrent control, randomized, open-label, assessor-blind, dose-ranging study of Org 31540/SR90107A in the prophylaxis of deep vein thrombosis in subjects undergoing total knee replacement surgery (PENTATAK).
96 Completed Steady-State Pharmacokinetics of Two Daily Oral Doses of Wellbutrin and Its Basic Metabolites in Normal Volunteers
999910/117 Completed Study to evaluate the immune response induced by DTPa/Hib and meningococcal C conjugate vaccines when given as a three-dose primary vaccination course in infants at 2, 3 and 4 months of age
999910/124 Completed A double blind, randomised, cross-over study to assess lamotrigine modulation of ketamine effects using functional magnetic resonance imaging in healthy male volunteers
999910/126 Completed A placebo-controlled, randomised, double-blinded, parallel group study in healthy volunteers to assess the effects of paroxetine on ejaculation and accompanying neurohumoral parameters.
999910/150 Completed A study in patients with Crohn's Disease to evaluate the effect of AVANDIA™ on inflammatory activity mediated by monocytes/macrophages. Study Listed on ClinicalStudyDataRequest.com
999910/189 Completed A comparison of the effects of AVANDIA® on arterial stiffness in obese subjects and healthy non-obese control subjects
999910/193 Completed Prospective, Hospital-based, Multicentre Study to Assess the Incidence of Intussusception in Children < 2 Years of Age in Singapore
999910/196 Completed A randomized, placebo-controlled, single blind, 4 way cross-over study to investigate the effects of a single dose of Avandia® on renal function in healthy male volunteers.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.